From MSN Money, November 2, 2009:
Hemispherx Biopharma updates chronic fatigue syndrome treatment and commercial application programs; plans to widen its ongoing clinical programs in CFS Co announces announces a two-prong CFS clinical mission for November and December 2009. The company plans to widen its ongoing clinical programs in C.F.S. by accelerating collaborations with a consortium of researchers who have just discovered a retroviral link to Chronic Fatigue Syndrome. With the consortium of researchers at the Whittemore Peterson Institute, the company is also now evaluating the defect in immunosurveillance in specific subsets of C.F.S. patients in a clinical study entitled "Therapeutic Activation of NK lymphocytes to Alleviate Chronic Fatigue Syndrome." These immune defects may be due to the previously undetected retrovirus. The company also plans to complete all outstanding queries from the FDA regarding its New Drug Application for Ampligen, an experimental therapeutic, during Nov and Dec, 2009. LINK
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment